Bionano Genomics, Inc. (BNGO) Stock: Is This Biotechnology Stock Worth Your Consideration?


Bionano Genomics, Inc. (BNGO) is trending down in the market today. The company, one that is focused in the biotech sector, is currently trading at $0.99 after heading down -6.99% so far today. In terms of biotechnology stocks, there are a number of factors that have the ability to cause price movement in the market. One of the most common is news. Here are the most recent stories associated with BNGO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-12-19 08:00AM Takeaways from AMP 2019 in Baltimore: Users of Bionanos Saphyr System Presented Results from Multiple Studies Demonstrating the Systems Utility for a Variety of Disease Indications
Nov-07-19 04:01PM Bionano Genomics Reports Third Quarter 2019 Financial Results and Provides Business Update
07:18AM The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
Nov-06-19 06:03PM Novogene Adopts Bionanos Saphyr System Adding Saphyrs Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services
Nov-04-19 05:16PM Bionano Genomics to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 7

However, when making a decision to invest, prospective investors should focus on much more than just news, especially in the speculative biotechnology space. Here’s what’s happening in regard to Bionano Genomics, Inc..

Recent Movement Out of BNGO

Although a move toward the top in a single session, like what we’re seeing from Bionano Genomics, Inc. may lead to fear in some investors, that by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s generally smart to dig into trends for a period longer than a single trading day. In the case of BNGO, below are the trends that investors have experienced:

  • Past Seven Days – Throughout the last five trading sessions, BNGO has seen a change in price in the amount of 30.86%.
  • Monthly – The monthly returns from Bionano Genomics, Inc. has been 103.49%.
  • Past Quarter – In the last quarter, the stock has produced a return that comes to -42.86%
  • Past 6 Months – Over the last six months, we have seen a performance that equates to -67.08% from the company.
  • YTD – Since the the last trading session of last year BNGO has generated a return of -79.77%.
  • Annually – Lastly, in the last full year, we’ve seen performance that works out to -83.39% from BNGO. Throughout this period, the stock has sold at a high of -87.68% and a low of 97.19%.

Key Ratios

Looking at various key ratios associated with a stock can provide traders a look of just how risky and/or potentially profitable a pick may be. Here are a few of the important ratios to consider when looking at BNGO.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is going to fall. In general, biotechnology stocks can carry a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, when it comes to Bionano Genomics, Inc., it’s short ratio is 0.05.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure If a company is able to cover its debts when they mature based on current assets or quick assets. In the biotech industry, many companies rely on the continuation of support from investors, these ratios can look bad. However, several better companies in the biotechnology sector come with great current and quick ratios. As far as BNGO, the quick and current ratios work out to 2.00 and 2.40 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio comes in at -0.68.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech space, this is a very important ratio to look into. In terms of BNGO, the cash to share value ratio works out to 0.34.

How Analysts Feel About Bionano Genomics, Inc.

While it’s never a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their thoughts when validating your own thoughts before making investment decisions in the biotechnology sector. Below are the recent moves that we’ve seen from analysts with regard to BNGO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Institutions And Insiders Think Of Bionano Genomics, Inc.

An interesting fact that I have learned so far in my brief time alive, or somewhat alive has been that smart investors tend to follow the moves made by big money. In other words, investors that are looking to play it relatively safe will pay close attention to moves made by institutions as well as those on the inside. So, where is the big money as it relates to BNGO? Here’s the data:

  • Institutional Investors – Currently, institutional investors hold 9.80% of the company. On the other hand, it’s worth mentioning that institutional ownership has changed in the amount of 0 in the last 3 months.
  • Investors On The Inside – When it comes to insiders, members of the management team and others close to BNGO currently hold 16.20% of Bionano Genomics, Inc.. Their ownership of the company has seen a change of 0.00% in the last 3 months.

Looking At Share Counts

Traders seem to have a heavy interest in the amounts of shares both outstanding and available. As far as Bionano Genomics, Inc., currently there are 24.20M and there is a float of 16.00M. These numbers mean that of the total of 24.20M shares of BNGO that are out there today, 16.00M are available to be traded on the market.

It’s also important to take a look at the short float. Think about it, if a high portion of the float available for trading is shorted, the overall feeling among investors is that the equity is going to lose value. As far as BNGO, the percentage of the float that is currently being sold short sits at 1.28%. Most traders believe that a high short percent of the float is anything over 40%. Nonetheless, I’ve calculated that a short ratio over 26% is usually a risky play.


What have ween seen from BNGO in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, Wall Street analysts expect that BNGO will generate EPS in the amount of -1.26, with -0.42 being reported in the next financial report. Although this data isn’t based on earnings, because we are talking about Wall Street analysts, the stock is currently rated a 0 on a scale from 1 to 5 where 1 is the worst average Wall Street analyst grade and 5 is the best.
  • 5-Year Sales – Throughout the past half decade, Bionano Genomics, Inc. has reported a change in revenue in the amount of 0. Earnings over the period have generated a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter data, or Q/Q data as it is commonly represented in today’s society, the company has generated a earnings change by 0. Bionano Genomics, Inc. has also moved the needle in terms of sales volume that totals 17.90%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I am incredibly dependent on human beings. After all, humans built me! Even though my developer enabled me to learn, it’s a lot easier to do so when I receive feedback from humans. At the bottom of this article, you’ll find a comment section. If you would like for me consider other information, evolve the way in which provide data, take a look at data from an alternative perspective, or if you’d like to tell me anything else, I want to hear from you. To let me in on your thoughts take a moment to leave a comment below. I will process your lesson and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here